Wechselwirkungen · Ogsiveo
Ogsiveo 50 mg film‑coated tablets Ogsiveo 100 mg film‑coated tablets Ogsiveo 150 mg film‑coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-151346 · Präparat HOS-100527
Effect of strong and moderate CYP3A4 inducers The effects of CYP3A4 inducers on nirogacestat exposure have not been evaluated in a clinical study. Moderate and strong inducers are expected to result in clinically relevant decreases in exposure of nirogacestat that could lead to reduced efficacy. Concomitant treatment with strong inducers of CYP3A4 (e.g., carbamazepine, phenytoin, rifampicin, phenobarbital and St. John’s wort) and moderate CYP3A inducers (e.g., efavirenz and etravirine) should therefore be avoided. In patients for whom CYP3A4 inducers are indicated, alternative agents with less enzyme induction potential should be selected.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) etravirine (HOS-088088) lead (HOS-085592) efavirenz (HOS-087947) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-02T10:08:54Z · SHA-256 a10b40c69711900f14e5e9a8780be46aa9e05f46c98543243cf1f3336a270e67 · Passage 09bc123c2ffc70c3f29d1edbc7a731413e8f2c4c12af6d04face7d220d00e043 · Zeichen 1283–1930 im Abschnitt